Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 14

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 the Company on each such date. Each Inducement Option Grant has a ten-year term and is subject to the terms
and conditions of the applicable stock option agreement. 

Total compensation cost related to stock options and
restricted stock awards was approximately $0.2 million of expense for period ended March 31, 2025 and $31,000 reversal for period ended
March 31, 2024. Of these amounts, approximately $49,000 for the period ended March 31, 2025 and $65,000 for the period ended March 31,
2024 were charged to research and development expenses and $0.2 million of expense for the period ended March 31, 2025 and $96,000 reversal
of expense for the period ended March 31, 2024 were charged to general and administrative expenses.

    11

A summary of stock option awards and
restricted stock grants, inclusive of awards granted under the 2018 Stock Plan and Inducement Option Grants for the three-months ended
March 31, 2025 is presented below:

 Summary of Stock Options Awards and Restricted Stock Grants

    Stock Options  
    Restricted Stock Awards  
    Weighted Average 

    Options Outstanding  
    Weighted Average Exercise Price  
    Non-vested Restricted Stock Outstanding  
    Weighted Average Grant Date Fair Value  
    Contractual Terms of Equity Awards (in years) 
  
    Equity awards outstanding at January 1, 2025 
     1,645,873  
    $1.95  
     39,700  
    $0.99  

    Equity awards granted 
     321,750  
    $0.86  
     -  
    $-  

    Equity awards terminated 
     (25,272) 
    $1.49  
     -  
    $-  

    Equity awards outstanding at March 31, 2025 
     1,942,351  
    $1.78  
     39,700  
    $0.99  
     8.7 

    Equity awards exercisable at March 31, 2025 
     1,095,121  
    $2.30  

     8.3 

    Aggregate intrinsic value of equity awards exercisable at March 31, 2025 
    $19,431